Skip to content

Alumis Inc. ALMS Return on assets

Return on assets at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
8.1%+2.5pp
Amgen logo
AmgenAMGN
8.6%+2.1pp
Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
-26.4%-10.7pp
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
6.8%+5.6pp
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
-45.4%-1,198pp
Immunome logo
ImmunomeIMNM
-46.7%-9.2pp

Other financials

Income statement

See full
Revenue$1.7M-90.0%
Operating income-$98.4M+3.1%
Net income-$93.1M+6.0%
EPS (diluted)-$0.74+59.3%

Balance sheet

See full
Cash & equivalents$63.9M-50.3%
Total debt$35.7M+1,881%
Total equity$567.0M+237%
Total assets$671.6M+157%

Cash flow

See full
Operating cash flow-$87.1M-8.4%
CapEx$164.0K+343%
Free cash flow-$87.2M-8.5%

Valuation

See full
Market cap$3.12B+739%
Enterprise value$3.1B+1,238%
P/S371.9×

Profitability

See full
Operating margin-5,364%
Net margin-2,825.7%
FCF margin-4,487.4%

Returns & leverage

See full
Return on equity-64.6%
Debt / equity0.1×+0.1×
Current ratio7.5×+3.8×

Where this comes from

Calculated from Alumis Inc.’s reported figures.

Based on trailing twelve months.

The official record: Alumis Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alumis Inc.'s return on assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Alumis Inc.'s return on assets?
Alumis Inc. (ALMS) reported return on assets of -50.9% in Q1 2026.
What does return on assets mean?
Trailing-twelve-month net income divided by average total assets. Measures how efficiently the asset base generates profit, independent of how those assets are financed. Computed as net income over average total assets — note this is OpenCapital's standard definition and may differ from data vendors that use alternative numerators.